Altered miRNA expression in pulmonary sarcoidosis

BMC Medical Genetics

Table 1 Clinical and biological characteristics of the study patients

	Stage I	Stages II-IV	Acute onset	Insidious onset
	n = 46	n = 48	n = 42	n = 51
Gender	25 F 21 M	22 F 26 M	22 F 20 M	24 F 27 M
Age	40.06	42.79	37.29	44.65
FEV₁, % pred.	94.30 ± 14.62	87.67 ± 17.31	98.18 ± 13.59	85.10 ± 16.10
FVC, % pred.	103.54 ± 13.46	96.55 ± 117.16	107.52 ± 11.56	93.93 ± 16.21
FEV₁/FVC	0.76 ± 0.07	0.747 ± 0.070	0.76 ± 0.07	0.74 ± 0.06
DLCOc, % pred.	-	90.73 ± 16.16	-	91.63 ± 16.69
BAL-L%	30.58 ± 18.00	29. 45 ±17.08	35.12 ± 16.62	25.79 ± 17.32
BALF CD4⁺/CD8⁺	6.84 ± 4.37	4.29 ± 3.66	7.98 ± 4.31	3.89 ± 3.18
Ca²⁺S, [mmol/l	2.44 ± 0.09	2.42 ± 0.18	2.41 ± 0.16	2.45 ± 0.13
Ca2 + U, mmol/24 hrs	4.83 ± 2.31	4.44 ± 2.66	4.24 ± 2.54	4.91 ± 2.46

Sarcoidosis patients were grouped according to the absence/presence of lung parenchymal changes on chest X-ray (stage I vs stage II-IV) and clinical phenotype (acute vs insidious onset). Abbreviations: BAL% broncholaveolar lavage - % of lymphocytes, Ca²⁺S serum calcium concentration, Ca²⁺U calcium in 24 hrs urine collection, DLCOc lung diffusion capacity for carbon monoxide corrected for hemoglobin, FEV₁ forced expiratory volume in 1st second of expiration, FVC forced vital capacity. Data are presented as mean ± standard deviation

ISSN: 1471-2350